IL2 and ovarian carcinoma: These preliminary observations and the high SDC1 and B-FN levels dosed in ascite from EOC patients afforded the possibility to investigate the effectiveness of a combined therapy using anti-SDC1 46F2SIP antibody and immunocytokine L19-IL2 in a human ovarian carcinoma model.